Welcome to our dedicated page for Fifty 1 Labs news (Ticker: FITY), a resource for investors and traders seeking the latest updates and insights on Fifty 1 Labs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fifty 1 Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fifty 1 Labs's position in the market.
Fifty 1 Labs (OTC: FITY) and UAV Corp (OTC: UMAV) have signed a Memorandum of Understanding on April 07, 2025, forming a strategic partnership to combat biohazards through integrated technology solutions. The collaboration combines UAV Corp's aerial systems with Genetic Networks' GeneScape™ platform to develop real-time detection systems for nuclear, chemical, and biological hazards.
The two-year partnership will focus on integrating 'sniffer' technologies into UAV Corp's airships and drones, with initial testing planned at UAV Corp's Wewahitchka facility. The collaboration leverages both companies' existing Department of Defense contracts and includes developing countermeasures deployable via aerial platforms.
Key initiatives include detection systems integration, countermeasure development, distribution partnership exploration, and joint R&D combining whole-genome analysis with UAV expertise. The partnership builds on FITY's recent SpaceX Fram2 mission experiment studying yeast resistance to microgravity and cosmic radiation.
Fifty 1 Labs (FITY) announces a major space research breakthrough through its subsidiary Genetic Networks, featuring groundbreaking yeast experiments on the recent SpaceX Fram2 mission. Led by Dr. Corey Nislow, the research builds on over a decade of space-based functional genomics, from the final Space Shuttle mission to Artemis I.
The latest experiment, launched on SpaceX's Fram2 mission, involves yeast strains engineered with tardigrade-derived transgenes to study their response to microgravity and cosmic radiation. This research aims to advance applications in human radiation therapy, particularly for cancer treatments.
Dr. Nislow's work focuses on understanding life's adaptation to space conditions, with implications for pharmaceutical development and space exploration. Genetic Networks plans to expand its SpaceX collaboration with multiple missions scheduled for 2025 and beyond, strengthening Fifty 1 Labs' position in biotechnology innovation both on Earth and in space.
Fifty 1 Labs (FITY) has acquired Genetic Networks for $10 million in common shares, appointing Dr. Gennaro D'Urso as CEO and Chairman. The acquisition brings the proprietary GeneScape™ platform, which integrates genomics, AI, and machine learning to accelerate drug discovery.
The GeneScape™ technology analyzes gene-drug interactions across 6,000 genes, reducing traditional drug development timelines from 9-12 years to 2-4 years. The platform offers applications in drug repurposing, biothreat research, and food additive testing.
Genetic Networks is currently negotiating multi-million dollar contracts with the Department of Defense (DoD) for developing biothreat countermeasures. The company plans to expand operations, enhance products, and secure partnerships with pharmaceutical companies.
4Cable TV International (CATV) has announced several strategic developments on March 20, 2025. The company facilitated the acquisition of Genetic Networks by Fifty 1 Labs, Inc. (FITY), which will result in a dividend distribution to CATV shareholders pending FINRA approval.
The company has significantly strengthened its financial position by eliminating $800,000 in debt and reducing 930 million dilutive shares, following a previous reduction of 7.8 billion shares on March 17, 2025. This brings the total share reduction to 8.7 billion shares.
Current Interim CEO Michael Feldenkrais will resign but oversee the transition as the company prepares for a reverse merger with a new company. The merger, expected in the coming weeks, will include a new name, ticker symbol, and management team.
Fifty 1 Labs (OTCPK: FITY), formerly Consumer Automotive Finance (OTCPK: CAFI), has completed its name and ticker symbol change with FINRA, now trading as FITY on the OTC market. The company, operating in the sports supplement, fitness equipment, and health and wellness sectors, has submitted responses to a second round of comments in its effort to regain SEC Rule 15c2-11 compliance.
The company has rescheduled its teleconference to March 17th, 2025, where management will discuss strategic direction and provide updates. CEO Brandon Spikes emphasized the importance of the name change in strengthening their market position and highlighted that regaining 15c2-11 compliance remains a priority for improving shareholder transparency and liquidity.
FAQ
What is the current stock price of Fifty 1 Labs (FITY)?
What is the market cap of Fifty 1 Labs (FITY)?
